Patent details

Basic Information

Publication number:

EP3823632

PCT Application Number:

US2019041508

Type:

European Patent Granted for LU

Legal Status:

In force

Application number:

EP198371296

PCT Publication Number:

WO2020018352

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

EFDA IN COMBINATION WITH DORAVIRINE FOR USE IN TREATING F227C MUTATED HIV INFECTIONS

French Title of Invention:

EFDA EN COMBINAISON AVEC LA DORAVIRINE POUR LE TRAITEMENT DES INFECTIONS PAR LE VIH MUTÉ F227C

German Title of Invention:

EFDA IN KOMBINATION MIT DORAVIRIN ZUR BEHANDLUNG VON F227C-MUTIERTEN HIV-INFEKTIONEN

SPC Number:

Dates

Filing date:

12/07/2019

Grant date:

29/10/2025

EP Publication Date:

26/05/2021

PCT Publication Date:

23/01/2020

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

29/10/2025

EP B1 Publication Date:

29/10/2025

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

12/07/2039

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

22/10/2025

 

 

Name:

Merck Sharp & Dohme LLC

Address:

126 East Lincoln Avenue, Rahway, New Jersey 07065, United States (US)

Inventor

1

Name:

LAI, Ming-Tain

Address:

United States (US)

2

Name:

HAZUDA, Daria Jean

Address:

United States (US)

Priority

Priority Number:

201862699047 P

Priority Date:

17/07/2018

Priority Country:

United States (US)

Classification

IPC classification:

A61K 31/7076; A61P 31/18; A61K 45/06; A61K 31/4439;

Publication

European Patent Bulletin

Issue number:

202544

Publication date:

29/10/2025

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

31/07/2026

Annual Fee Number:

8

Annual Fee Amount:

99 Euro

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages